195 related articles for article (PubMed ID: 32694239)
1. Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma.
Hou S; Chen X; Li M; Huang X; Liao H; Tian B
Aging (Albany NY); 2020 Jul; 12(14):14542-14555. PubMed ID: 32694239
[TBL] [Abstract][Full Text] [Related]
2. CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC).
Tian Y; Wu J; Chagas C; Du Y; Lyu H; He Y; Qi S; Peng Y; Hu J
BMC Cancer; 2018 Nov; 18(1):1187. PubMed ID: 30497429
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of
Bai L; Ren Y; Cui T
J Comput Biol; 2020 Jun; 27(6):965-974. PubMed ID: 31593490
[TBL] [Abstract][Full Text] [Related]
4. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of h-prune as a potential therapeutic target for hepatocellular carcinoma.
Liao H; Liao M; Xu L; Yan X; Ren B; Zhu Z; Yuan K; Zeng Y
EBioMedicine; 2019 Mar; 41():310-319. PubMed ID: 30665854
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of CDCA5 promotes gastric cancer malignant progression via influencing cyclin E1.
Zhang Z; Shen M; Zhou G
Biochem Biophys Res Commun; 2018 Feb; 496(2):482-489. PubMed ID: 29326043
[TBL] [Abstract][Full Text] [Related]
7. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.
Li S; Huang J; Yang F; Zeng H; Tong Y; Li K
Sci Rep; 2021 May; 11(1):11078. PubMed ID: 34040099
[TBL] [Abstract][Full Text] [Related]
8. Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma.
Zhang YF; Wang YX; Zhang N; Lin ZH; Wang LR; Feng Y; Pan Q; Wang L
Bioengineered; 2021 Dec; 12(1):1202-1211. PubMed ID: 33830865
[TBL] [Abstract][Full Text] [Related]
9. Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma.
Kong J; Yu G; Si W; Li G; Chai J; Liu Y; Liu J
BMC Cancer; 2022 Feb; 22(1):142. PubMed ID: 35123420
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of targeting cell division cycle associated 5 for oral squamous cell carcinoma.
Tokuzen N; Nakashiro K; Tanaka H; Iwamoto K; Hamakawa H
Oncotarget; 2016 Jan; 7(3):2343-53. PubMed ID: 26497678
[TBL] [Abstract][Full Text] [Related]
11. Silencing oncogene cell division cycle associated 5 induces apoptosis and G1 phase arrest of non-small cell lung cancer cells via p53-p21 signaling pathway.
Shen W; Tong D; Chen J; Li H; Hu Z; Xu S; He S; Ge Z; Zhang J; Mao Q; Chen H; Xu G
J Clin Lab Anal; 2022 May; 36(5):e24396. PubMed ID: 35373420
[TBL] [Abstract][Full Text] [Related]
12. KLF5-mediated CDCA5 expression promotes tumor development and progression of epithelial ovarian carcinoma.
Chen X; Zhou M; Ma S; Wu H; Cai H
Exp Cell Res; 2023 Aug; 429(1):113645. PubMed ID: 37247719
[TBL] [Abstract][Full Text] [Related]
13. Loss of cell division cycle‑associated 5 promotes cell apoptosis by activating DNA damage response in clear cell renal cell carcinoma.
Huang X; Huang Y; Lv Z; Wang T; Feng H; Wang H; Du S; Wu S; Shen D; Wang C; Li H; Wang B; Ma X; Zhang X
Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35642672
[TBL] [Abstract][Full Text] [Related]
14. Aberrantly DNA Methylated-Differentially Expressed Genes and Pathways in Hepatocellular Carcinoma.
Cai C; Wang W; Tu Z
J Cancer; 2019; 10(2):355-366. PubMed ID: 30719129
[No Abstract] [Full Text] [Related]
15. Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma.
Xu T; Ma M; Dai J; Yu S; Wu X; Tang H; Yu J; Yan J; Yu H; Chi Z; Si L; Sheng X; Cui C; Kong Y; Guo J
Hum Pathol; 2018 May; 75():137-145. PubMed ID: 29452217
[TBL] [Abstract][Full Text] [Related]
16. Systematic cancer-testis gene expression analysis identified CDCA5 as a potential therapeutic target in esophageal squamous cell carcinoma.
Xu J; Zhu C; Yu Y; Wu W; Cao J; Li Z; Dai J; Wang C; Tang Y; Zhu Q; Wang J; Wen W; Xue L; Zhen F; Liu J; Huang C; Zhao F; Zhou Y; He Z; Pan X; Wei H; Zhu Y; He Y; Que J; Luo J; Chen L; Wang W
EBioMedicine; 2019 Aug; 46():54-65. PubMed ID: 31324603
[TBL] [Abstract][Full Text] [Related]
17. High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma.
Guan Z; Cheng W; Huang D; Wei A
Curr Res Transl Med; 2018 Mar; 66(1):27-32. PubMed ID: 29274707
[TBL] [Abstract][Full Text] [Related]
18. CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.
Ji J; Shen T; Li Y; Liu Y; Shang Z; Niu Y
Oncol Rep; 2021 Mar; 45(3):921-932. PubMed ID: 33650660
[TBL] [Abstract][Full Text] [Related]
19. Cell division cycle associated 2 (CDCA2) upregulation promotes the progression of hepatocellular carcinoma in a p53-dependant manner.
Wang J; Liu X; Chu H; Chen J
PeerJ; 2022; 10():e13535. PubMed ID: 35694386
[TBL] [Abstract][Full Text] [Related]
20. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
